Enhancing innate anti-tumour immunity : lessons from virotherapy and STING agonism 2 / Kevin J. Harrington.

Format:

Video

Author/Creator:

Harrington, Kevin J., author.

Language:

English

Subjects (All):

Cancer--Immunotherapy.

Cancer.

Clinical trials.

Physical Description:

1 streaming video file (18 min., 44 sec.) : color, sound

Other Title:

Enhancing innate anti-tumour immunity

Place of Publication:

London : Henry Stewart Talks Ltd, 2024.

System Details:

video file

Contents:

Introduction

IGNYTE - Phase 2 study design

Demographics

Treatment-related AEs

IGNYTE data: ORR

Waterfall plots: all patients

Spider plots: all patients

Swimmer's plots: all patients

Timing and duration of prior anti-PD1 therapy

Preliminary PFS and OS

Patient 1121-2011: forehead

Patient 1121-2011

Patient 4405-2007

Patient 4405-2007: lung

Summary & conclusions

Phase 1/2 clinical trial of RP1 alone & combined with nivolumab

Patient 2 (4402-2001): ongoing CR

Patient 2 (4402-2001): scans

Patient 2 (4402-2001): further response

Patient 2 (4402-2001): CD8 T cell & PD-L1 staining

Patient 5 (4402-2005)

Activation of pattern recognition receptors

TLR-based therapeutics

Toll-like receptors and their agonists

Intralesional SD-101 in combination with pembrolizumab

Activation of pattern recognition receptors: STING

Preliminary results of the FIH study of MK-1454

Baseline characteristics

Pharmacodynamic biomarkers

Waterfall plot of combination therapy

Example from 2 patients

Phase I dose-escalation trial of MIW815

Response data

Conclusions

Acknowledgments

Declaration of interests.

Notes:

Description based on publisher supplied metadata and other sources.

Retrieved August 28, 2025, from https://doi.org/10.69645/CGTZ7509.